MWG Biotech to divest genomic diagnosis:
This article was originally published in Clinica
Ebersberg, Germany-based MWG Biotech has decided to distance itself from certain non-core business lines, including genomic diagnosis. Board member Wolfgang Pieken said the company was confident of finding new partners for the businesses to be divested. They "contain highly innovative and recognised product and service portfolios", he said. MWG's genomic diagnosis business makes DNA microarrays for use in research. Its Genomic Technology business, focused on laboratory automation, will also be divested. The company will focus on gene sequencing and genomic synthesis.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.